FY2024 EPS Estimates for CRVS Reduced by Cantor Fitzgerald

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Analysts at Cantor Fitzgerald cut their FY2024 EPS estimates for Corvus Pharmaceuticals in a note issued to investors on Wednesday, November 13th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will earn ($0.91) per share for the year, down from their prior estimate of ($0.50). The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.68) per share.

Several other research firms have also recently issued reports on CRVS. Mizuho raised Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 22nd. StockNews.com downgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. Oppenheimer raised their target price on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Finally, LADENBURG THALM/SH SH raised their price objective on Corvus Pharmaceuticals from $12.00 to $21.00 and gave the company a “buy” rating in a research report on Monday, September 16th. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $12.83.

Corvus Pharmaceuticals Price Performance

CRVS opened at $8.40 on Monday. The firm has a market capitalization of $539.78 million, a price-to-earnings ratio of -9.03 and a beta of 1.05. Corvus Pharmaceuticals has a one year low of $1.30 and a one year high of $10.00. The business has a 50 day simple moving average of $6.92 and a two-hundred day simple moving average of $4.13.

Institutional Trading of Corvus Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Nwam LLC purchased a new position in Corvus Pharmaceuticals during the third quarter valued at $53,000. XTX Topco Ltd purchased a new position in shares of Corvus Pharmaceuticals in the 3rd quarter worth about $74,000. Avity Investment Management Inc. boosted its stake in Corvus Pharmaceuticals by 138.2% in the 3rd quarter. Avity Investment Management Inc. now owns 27,580 shares of the company’s stock worth $146,000 after purchasing an additional 16,000 shares in the last quarter. Oppenheimer & Co. Inc. bought a new position in Corvus Pharmaceuticals in the 3rd quarter worth about $89,000. Finally, Towerview LLC grew its position in Corvus Pharmaceuticals by 4.6% during the 2nd quarter. Towerview LLC now owns 400,000 shares of the company’s stock valued at $728,000 after purchasing an additional 17,500 shares during the last quarter. 46.64% of the stock is owned by institutional investors.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.